Vanguard Group Inc Lumos Pharma, Inc. Call Options Transaction History
Vanguard Group Inc
- $5.12 Trillion
- Q2 2024
Call Options
0 transactions
| Quarter | Operation | Price Per call | calls change | calls Held | SEC Form |
|---|
Others Institutions Holding LUMO
# of Institutions
38Shares Held
2.88MCall Options Held
0Put Options Held
0-
Private Advisor Group, LLC745KShares$3.25 Million0.02% of portfolio
-
Wells Fargo & Company San Francisco, CA415KShares$1.81 Million0.0% of portfolio
-
Goldman Sachs Group Inc New York, NY407KShares$1.78 Million0.0% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny216KShares$943,1070.0% of portfolio
-
Acuitas Investments, LLC141KShares$618,0700.19% of portfolio
About LUMOS PHARMA, INC.
- Ticker LUMO
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 8,396,070
- Market Cap $36.7M
- Description
- Lumos Pharma, Inc., a clinical-stage biopharmaceutical company, focuses on the development and commercialization of therapeutics for rare diseases. Its lead therapeutic candidate LUM-201 is an oral growth hormone secretagogue ibutamoren, which is in Phase 2 clinical trial for the treatment of pediatric growth hormone deficiency and other rare en...